REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Update

REGENXBIO Inc. (NASDAQ:RGNX) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 6.1 days.

Analyst Upgrades and Downgrades

RGNX has been the subject of several research reports. Raymond James reiterated an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, HC Wainwright decreased their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Stock Up 6.9 %

Shares of NASDAQ:RGNX opened at $7.73 on Wednesday. REGENXBIO has a fifty-two week low of $7.14 and a fifty-two week high of $28.80. The firm’s 50-day simple moving average is $9.17 and its 200-day simple moving average is $10.86. The company has a market cap of $382.98 million, a price-to-earnings ratio of -1.54 and a beta of 1.24.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System raised its stake in shares of REGENXBIO by 14.0% during the second quarter. Louisiana State Employees Retirement System now owns 22,800 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 2,800 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of REGENXBIO by 9.3% during the second quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company’s stock valued at $3,972,000 after purchasing an additional 28,846 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of REGENXBIO by 4.3% in the 2nd quarter. Principal Financial Group Inc. now owns 225,417 shares of the biotechnology company’s stock worth $2,637,000 after acquiring an additional 9,206 shares during the period. Maryland State Retirement & Pension System raised its holdings in shares of REGENXBIO by 7.2% during the second quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,067 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in REGENXBIO by 8.2% in the 2nd quarter. Rhumbline Advisers now owns 118,526 shares of the biotechnology company’s stock worth $1,387,000 after buying an additional 8,987 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.